Apparatuses, Compositions, and Methods for Prolonging Survival of Platelets
AssigneeVelico Medical, Inc.
InventorsKeith Rosiello, Henrik Clausen
Life of this patent
Estimating the term…
Abstract
The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis.
Claims26
An apparatus for processing a sample of platelets, the apparatus comprising a first sterile container having one or more ports including a first container port and containing a preparation of blood cells comprising platelets, a second sterile container having one or more ports including a second container port and containing a blood cell modifying agent which comprises cytidine 5′-monophospho-N-acetylneuraminic acid, the first container being adapted to the second container through a first sterile conduit reversibly attachable to the first container port and the second container port, the first sterile conduit further comprising a valve, wherein the blood cell modifying agent present in the second sterile container is introduced into the first sterile container and the platelets in the preparation of blood cells therein are rendered cold storage competent after the platelets are contacted with the blood cell modifying agent.
An apparatus for processing a sample of platelets, the apparatus comprising a first sterile container having one or more ports and containing a blood cell modifying agent which comprises cytidine 5′-monophospho-N-acetylneuraminic acid, and an array comprising a first conduit and a plurality of sterile docks, wherein each of the sterile docks is reversible adaptable to blood storage containers, the blood storage containers having a sample of blood cells comprising platelets and further comprising at least one port for connecting to the sterile docks of the array, wherein the platelets are introduced into the first sterile container through the conduit and are rendered cold storage competent by contacting the platelets with the blood cell modifying agent present in the sterile first container.
An apparatus for processing a sample of platelets, the apparatus comprising a first sterile container having one or more ports, the first container further comprising a subcontainer disposed therein, the subcontainer having a port and a frangible barrier and containing a blood cell modifying agent which comprises cytidine 5′-monophospho-N-acetylneuraminic acid, and an array comprising a conduit and a plurality of sterile docks, wherein each of the sterile docks is reversible adaptable to blood storage containers, the blood storage containers having a sample of blood cells comprising platelets and further comprising at least one port for connecting to the sterile docks of the array, wherein the platelets are introduced into the first sterile container through the conduit and are rendered cold storage competent after the platelets are contacted with the blood cell modifying agent present in the first sterile container.
A method for treating a platelet using an apparatus, wherein the apparatus is selected from the group consisting of:
- a. an apparatus comprising a first sterile container having one or more ports including a first container port and containing a preparation of blood cells comprising platelets, a second sterile container having one or more ports including a second container port and containing a blood cell modifying agent, the first container being adapted to the second container through a first sterile conduit reversibly attachable to the first container port and the second container port, the first sterile conduit further comprising a valve;
- b. an apparatus comprising a first sterile container having one or more ports and containing a blood cell modifying agent, and an array comprising a first conduit and a plurality of sterile docks, wherein each of the sterile docks is reversible adaptable to blood storage containers, the blood storage containers having a sample of blood cells comprising platelets and further comprising at least one port for connecting to the sterile docks of the array;
- and
- c. an apparatus comprising a first sterile container having one or more ports, the first container further comprising a subcontainer disposed therein, the subcontainer having a port and a frangible barrier and containing a blood cell modifying agent, and an array comprising a conduit and a plurality of sterile docks, wherein each of the sterile docks is reversible adaptable to blood storage containers, the blood storage containers having a sample of blood cells comprising platelets and further comprising at least one port for connecting to the sterile docks of the array;
- wherein the steps of the method comprise contacting the platelets with the one or more blood cell modifying agents, wherein the one or more blood cell modifying agents comprise cytidine 5′-monophospho-N-acetylneuraminic acid or both UDP-galactose and cytidine 5′-monophospho-N-acetylneuraminic acid, to thereby obtain treated platelets.
A treated blood cell obtained through a method for treating a platelet using an apparatus, wherein the apparatus is selected from the group consisting of:
- a. an apparatus comprising a first sterile container having one or more ports including a first container port and containing a preparation of blood cells comprising platelets, a second sterile container having one or more ports including a second container port and containing a blood cell modifying agent, the first container being adapted to the second container through a first sterile conduit reversibly attachable to the first container port and the second container port, the first sterile conduit further comprising a valve;
- b. an apparatus comprising a first sterile container having one or more ports and containing a blood cell modifying agent, and an array comprising a first conduit and a plurality of sterile docks, wherein each of the sterile docks is reversible adaptable to blood storage containers, the blood storage containers having a sample of blood cells comprising platelets and further comprising at least one port for connecting to the sterile docks of the array;
- and
- c. an apparatus comprising a first sterile container having one or more ports, the first container further comprising a subcontainer disposed therein, the subcontainer having a port and a frangible barrier and containing a blood cell modifying agent, and an array comprising a conduit and a plurality of sterile docks, wherein each of the sterile docks is reversible adaptable to blood storage containers, the blood storage containers having a sample of blood cells comprising platelets and further comprising at least one port for connecting to the sterile docks of the array;
- wherein the steps of the method comprise processing the platelets using the apparatus such that the platelets are exposed to the two or more blood cell modifying agents that include cytidine 5′-monophospho-N-acetylneuraminic acid or both UDP-galactose and cytidine 5′-monophospho-N-acetylneuraminic acid.
Dependencies are inferred from the claim text.